Drug Target ID was established in 2012 in Nijmegen, the Netherlands as a spin-out company of Radboud University. We now work completely independently, but retain an academic affeliation with Radboud University Medical Center. Our academic connections enable us to work at the interface between the scientific community and the pharmacological industry.

DTID has a broad expertise in the analysis of complex (genetic) diseases and collaborates with world-leading academic institutes and consortia as well as pharmaceutical companies to advance the discovery of new drug targets and treatments.

Mercator2 Science Park
The building on the Radboud University campus where DTID is located


Geert Poelmans

Geert Poelmans, M.D., Ph.D.
Director & Chief Scientific Officer

Geert is a medical doctor (M.D., University of Leuven, Belgium) and has a Ph.D. (cum laude, Radboud University, The Netherlands). He has extensive experience and expertise in (child and adolescent) psychiatry and molecular as well as clinical genetics. In 2012, Geert founded DTID, based on the molecular landscape building approach that he pioneered and developed during his Ph.D. research. Geert retains an academic affiliation with Radboud University Medical Center.

Koen Klemann

Koen Klemann, Ph.D.
Project manager

Koen obtained a M.Sc. in Molecular Life Sciences at Radboud University (cum laude, 2011) and a Ph.D. on amyotrophic lateral sclerosis and Parkinson’s disease in 2017 (Radboud University). During his Ph.D. trajectory Koen joined DTID to build molecular landscapes for complex diseases. Koen works on the constant further development of our molecular landscape building approach for drug target identification, aiming to incorporate the latest cutting-edge technologies.

Ward De Witte, B.Sc.

Ward De Witte, B.Sc.

Ward is a bioinformatician (HAN University of Applied Sciences, Nijmegen, The Netherlands) and he conducts elaborate data analyses to advance our drug discovery efforts. His expertise in the analysis of biological data and computational methods plays an important role in identifying putative drug targets, making valuable contributions to DTID’s mission.

Joanna Widomska, Ph.D.

Joanna Widomska, Ph.D.
Research Scientist

Joanna has a background in biotechnology and holds a Ph.D. in medical sciences from Radboud University. Through international academic and work experience, she has built a board expertise in omics data design, analysis, integration and interpretation. Since 2017, Joanna is part of the DTID team, where she continues to develop and implement computational research and methods to better understand molecular processes in health and disease.

Huyn Ruisch, M.D., Ph.D.
Clinical Scientist

Hyun is a medical doctor and has a Ph.D. in genetics (University of Groningen, The Netherlands). He has a clinical background in psychiatry and during his PhD, Hyun joined DTID. At DTID, he is building molecular landscapes as part of PRIME, an ongoing EU project about insulin-related diseases in the brain (e.g. Alzheimer’s disease) and the body (e.g. diabetes mellitus). Hyun also works at the Accare Child Study Center in Groningen.

Marco Heerings, M.A.N.P.

In 2002, Marco graduated from the University of Applied Science Groningen, The Netherlands, with a Master in Advanced Nursing Practice. In 2018, Marco joined DTID as a Ph.D. candidate on the project: Genetics of Multiple Sclerosis in Interaction with the gut Microbiome (The GEMSIM study). Marco is expected to defend his thesis in 2024.

Scroll to Top